Here's What Key Metrics Tell Us About Teleflex (TFX) Q1 Earnings

Core Insights - Teleflex reported revenue of $700.67 million for the quarter ended March 2025, a decrease of 5% year-over-year, with EPS at $2.91 compared to $3.21 in the same quarter last year, indicating a slight revenue surprise of +0.22% over the Zacks Consensus Estimate and an EPS surprise of +1.04% [1] Financial Performance - Revenue breakdown shows significant geographic performance: - Americas: $475.70 million, exceeding the estimated $418.41 million, reflecting a +17.1% year-over-year change - Asia: $73.80 million, below the estimated $77.13 million - EMEA: $151.20 million, slightly below the estimated $154.16 million [4] - Net revenues in key segments: - Interventional: $137.50 million, close to the estimated $137.85 million, with a +2.1% year-over-year change - Interventional Urology: $71 million, above the estimated $69.11 million, but down -10.9% year-over-year - OEM: $63.90 million, below the estimated $70.27 million, down -27.1% year-over-year - Vascular Access: $182.40 million, slightly above the estimated $178.12 million, with a +0.6% year-over-year change - Anesthesia: $86.60 million, below the estimated $92.40 million, down -10.2% year-over-year - Other: $53.50 million, above the estimated $49.30 million, with a +2.1% year-over-year change - Surgical: $105.80 million, above the estimated $102.08 million, with a +0.3% year-over-year change [4] Market Performance - Teleflex shares have returned -3.1% over the past month, compared to the Zacks S&P 500 composite's -0.7% change, indicating underperformance relative to the broader market [3]